Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation
2024

Understanding Poor Graft Function After Stem Cell Transplantation

Sample size: 832 publication 10 minutes Evidence: high

Author Information

Author(s): Konradin F. Müskens, Winny N. R. Collot-d'Escury, Rana Dandis, Saskia Haitjema, Jürgen Kuball, Moniek A. de Witte, Marc Bierings, Caroline A. Lindemans, Stefan Nierkens, Mirjam E. Belderbos

Primary Institution: Princess Máxima Center for Pediatric Oncology

Hypothesis

How does the definition of poor graft function (PGF) affect its reported incidence and outcomes in hematopoietic cell transplantation?

Conclusion

The study shows that differences in PGF definitions significantly impact the reported incidence, risk factors, and outcomes, highlighting the need for standardized definitions.

Supporting Evidence

  • The study analyzed over 35,000 blood counts from HCT recipients.
  • 97 pediatric and 75 adult patients were identified with PGF.
  • The 2-year cumulative incidence of PGF varied significantly based on the definition used.
  • Mortality rates for PGF patients ranged from 33% to 65% depending on the definition.
  • Older recipient age and cord blood transplantation were identified as risk factors for PGF.
  • Standardized definitions are needed to improve treatment strategies for PGF.
  • Different definitions resulted in a threefold difference in PGF classification.
  • Patients with mild PGF had similar mortality to those with good graft function.

Takeaway

This study looked at how different ways of defining poor graft function after a stem cell transplant can change the numbers and outcomes for patients. It shows we need to agree on one clear definition.

Methodology

The study analyzed over 35,000 blood counts from 427 pediatric and 405 adult HCT recipients to compare PGF incidence and outcomes based on different definitions.

Potential Biases

The retrospective nature of the study may introduce bias in treatment decisions and outcomes.

Limitations

The study excluded patients who died within 28 days post-transplant and those with insufficient blood count data, which may limit the generalizability of the findings.

Participant Demographics

{"pediatric":{"n":427,"median_age":8.4,"sex_distribution":{"male":56.4,"female":43.4}},"adult":{"n":405,"median_age":55.8,"sex_distribution":{"male":61.0,"female":39.0}}}

Statistical Information

Confidence Interval

95% CI: 4.7%–9.4% for pediatric PGF incidence

Digital Object Identifier (DOI)

10.1002/hem3.70059

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication